VitroScan’s proven effective Predictive Tumor Testing Platform is developed for patient stratification to enrich trail populations, thereby improving probability of success, decrease the number of patients per trail, fast track FDA & EMA approval and saving tremendous amounts of costs regularly involved in clinical trials.
VitroScan develops rapid and certified testing (2 weeks turnaround time) to rank the patient’s sensitivity to novel cancer therapies. Patient derived tumor tissues is tested for all relevant drug classes, chemotherapy, small molecules, antibodies, ADC’s, immunotherapies. Our proprietary technology pipeline provides accurate ex vivo testing in a preserved tumor microenvironment and applies image based analysis to identify the treatment sensitive and insensitive patients.
Discuss your clinical trial stratification needs with our expert team.